Platelet-activating Factor and Skin Burn Inflammation
Official title: Platelet-activating Factor and Epidermal Cytotoxicity
Funded at Wright State University · NIH-11363235 · Data updated 2026-11-12
This project looks at how a fat molecule called PAF drives inflammation after severe burns and whether blocking it could help people recover.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wright State University NIH-funded |
| Lab location | 1 site (Dayton, United States) |
| Project start | August 1, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $429,136 |
| NIH project number | 9R01AR087686-23A1 |
| Project ID | NIH-11363235 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with severe burn injuries or conditions related to burn-induced inflammation may be eligible for related studies.
✕Less likely to help
Individuals without severe burns or without involvement of PAF-related pathways may not benefit.
What this research studies
After severe burns, the body overreacts with inflammation that can lead to organ problems. The research uses animal models and human-focused experiments to understand how the PAF molecule and its receptor contribute to this response. The team aims to pinpoint targets that could be blocked to lessen organ damage and improve healing after burns. If successful, this work could pave the way for new treatments that reduce complications and deaths from large burns.
Why it matters
Potential benefit: Could lead to new therapies that reduce inflammation and organ injury after severe burns.
How similar studies have gone: Previous work has shown PAF-related inflammation can mimic septic shock, supporting potential for targeted therapies, though translation to humans remains ongoing.
Where this research is happening
-
Wright State University
Dayton, United States Active
Researchers
- Principal investigator: Travers, Jeffrey B. — Wright State University
- Study coordinator: Travers, Jeffrey B.
Related research
Other NIH-funded projects on the same topics.
-
Excitability dysfunction in ALS and FTD linked to TDP-43
A patient-focused research opportunity to understand how nerve cell electrical activity goes wrong in ALS and related dementia linked to TDP-43.
-
Glycosylation changes that boost heart signals and lead to heart failure
A study to understand how changes in sugar attachments on heart cell receptors may fuel heart failure, with potential to guide new treatments.
-
Regulation of TRPM7 in low and high magnesium conditions
This grant studies how the TRPM7 ion channel and enzyme influence immune cell function when magnesium levels change, which could affect immune responses in people.
-
Lipin1 and Micro-Dystrophin Gene Therapies for DMD: A New Dual Approach
A study to explore whether boosting Lipin1 together with micro-dystrophin gene therapy could improve muscle and heart health in Duchenne muscular dystrophy patients.
-
Neuromuscular Junction Problems in Hyperkalemic Paralysis
A clinician-scientist is pursuing five years of advanced training and research to better understand and care for people with neuromuscular diseases related to hyperkalemic paralysis.
-
Understanding why nerve cells in ALS and FTD misfire and how to help them
Aims to understand why motor neurons become over- or under-responsive in ALS and related brain disorders using a mouse model that mimics human disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.